2024
The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatment
2023
Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach.
Radwan R, Hertz D, Hickey E, Vachhani H, Lustberg M, Bridges J, Sabo R, Sheppard V, Salgado T. Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach. Journal Of Clinical Oncology 2023, 41: e13123-e13123. DOI: 10.1200/jco.2023.41.16_suppl.e13123.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyMetastatic breast cancerPeripheral neuropathyTreatment alterationsTreatment effectivenessMBC patientsCIPN symptomsMedical oncologistsDiscontinue treatmentClinical guidelinesOncology cliniciansCommunity-centered approachEffective therapyBreast cancerChemotherapy agentsTreatment decisionsPatient prioritiesPatient's perspectiveDose reductionAlternative treatmentOptimize outcomesPatientsSide effectsTreatment planHealthcare providers
2021
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
Park KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V, Sharma P, Pusztai L, Shen C, Partridge A, Thompson A. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Research And Treatment 2021, 188: 249-258. PMID: 33651271, PMCID: PMC7921279, DOI: 10.1007/s10549-021-06153-3.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionNeoadjuvant endocrine therapyMedical oncologistsRadiation oncologistsOmission of ALNDEstrogen positive breast cancer patientsPositive breast cancer patientsEarly-stage breast cancerEndocrine therapy useMetastatic axillary diseaseLymph node dissectionBreast cancer patientsMultidisciplinary tumor boardStage breast cancerClinical trial organizationsPercent of practicesUS medical oncologistsCOVID-19 pandemicPre-pandemic timesRegional COVID-19 casesAxillary diseaseMicrometastatic nodesSurgery 2Endocrine therapyLocoregional management
2020
Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients.
Johns K, Kalister S, Mwandha N, Adams E, Basinger H, Fugett S, Crawford D, Draime M, Shinde N, Kassem M, Radcliff L, Unthank B, Cherian M, Sardesai S, Stover D, Vandeusen J, Wesolowski R, Williams N, Ramaswamy B, Lustberg M. Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients. Journal Of Clinical Oncology 2020, 38: e14004-e14004. DOI: 10.1200/jco.2020.38.15_suppl.e14004.Peer-Reviewed Original ResearchCollaborative care modelPHQ-9 scoresCare modelCancer patientsPHQ-9Satisfaction scoresAverage patient satisfaction scoreRegular case reviewBreast cancer patientsPatient satisfaction scoresGAD-7 scoresInitial scoresMental health servicesMental health careMental health resourcesTeam-based modelForms of cancerEndocrine therapyClinical suspicionExcess morbidityMedian ageMedical oncologistsBC patientsCDK4/6 inhibitorsCancer population
2013
Integrative model for breast cancer survivorship.
Reinbolt R, Shapiro C, Garrett J, Basinger H, Lester J, Muscari N, Ries K, Lustberg M. Integrative model for breast cancer survivorship. Journal Of Clinical Oncology 2013, 31: 132-132. DOI: 10.1200/jco.2013.31.26_suppl.132.Peer-Reviewed Original ResearchElectronic medical recordsIntegrative care modelCare plansMedical recordsCare modelCancer survivorship care planningSurvivorship care planningIndividualized care plansBreast cancer survivorshipCross-sectional studyGroup educational sessionsEarly survivorshipBetter address needsSmart phrasesMedical oncologistsPrimary nurseTreatment summaryDistress ThermometerIndividual patientsCancer survivorshipNurse practitionersCare planningBreast programPhysical symptomsPatients